Certified Advisory Corp Has $2.32 Million Holdings in Pfizer Inc. (NYSE:PFE)

Certified Advisory Corp raised its position in Pfizer Inc. (NYSE:PFE) by 1.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 82,840 shares of the biopharmaceutical company’s stock after purchasing an additional 1,313 shares during the period. Certified Advisory Corp’s holdings in Pfizer were worth $2,318,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Estabrook Capital Management lifted its holdings in Pfizer by 0.3% in the second quarter. Estabrook Capital Management now owns 361,026 shares of the biopharmaceutical company’s stock valued at $10,102,000 after buying an additional 1,148 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Pfizer by 33.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 34,627 shares of the biopharmaceutical company’s stock worth $1,058,000 after acquiring an additional 8,681 shares in the last quarter. Fairscale Capital LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at about $179,000. Gabelli Funds LLC boosted its position in shares of Pfizer by 4.5% during the 2nd quarter. Gabelli Funds LLC now owns 742,113 shares of the biopharmaceutical company’s stock valued at $20,764,000 after purchasing an additional 31,700 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its stake in Pfizer by 1.7% during the second quarter. Fidelis Capital Partners LLC now owns 24,568 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 412 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Trading Down 0.8 %

NYSE PFE opened at $29.42 on Monday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $29.36 and a 200 day simple moving average of $28.24. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.11. The firm has a market capitalization of $166.71 billion, a P/E ratio of -490.25, a PEG ratio of 1.05 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.71%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.